Researchers from VCU Massey Cancer Center, the University of Florida College of Medicine, and UF Health Cancer Center found that minority patient participation in cancer clinical trials is low—in part due to standard clinical trial criteria that disproportionately exclude Black patients.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
